An ASNC Information Statement: Radiopharmaceutical supply disruptions and the use of 99mTc-hydroxymethylene diphosphonate as an alternative to 99mTc-pyrophosphate for the diagnosis of transthyretin cardiac amyloidosis
Resource Type
Information Statements, Practice Points
Year Published
2022
Related Resources
Cases
PET Case: Identifying Epicardial Coronary Artery Disease in a Patient With Paroxysmal Atrial Fibrillation Using [15O]H2O PET
Case summary: This case highlights the ability of [15O]H2O PET to accurately…
Health Policy Memos
ASNC, ACC Comment to Commerce Department on Radiopharmaceutical Imports
ASNC-ACC-Radiopharms-Tariff-Letter_05-07-2025 ASNC and the American College of Cardiology submitted comments on a…
Cases
PET Case: Very High-Risk PET MPI
Case summary: This case illustrates the value of cardiac PET MPI for…
